Ractigen's RAG-01 Shows Promising Early Complete Responses in Phase I NMIBC Trial, Data Presented at EAU 2025

Ractigen's RAG-01 Shows Promising Early Complete Responses in Phase I NMIBC Trial, Data Presented at EAU 2025

NANTONG, China and MELBOURNE, Australia, March 24, 2025 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage biopharmaceutical company pioneering small activating RNA (saRNA) therapeutics, today announced the presentation of positive preliminary...

Ractigen Therapeutics Founder Dr. Long-Cheng Li Awarded 2024 Life Science Ice Breaking Award

Ractigen Therapeutics Founder Dr. Long-Cheng Li Awarded 2024 Life Science Ice Breaking Award

NANTONG and SUZHOU, China, Dec. 31, 2024 /PRNewswire/ -- Ractigen Therapeutics proudly announces that its Founder and CEO, Dr. Long-Cheng Li, has been honored with the 2024 Life Science Ice Breaking Award. This award, established by Mr. Cai Lei, a...

Ractigen Therapeutics Announces First Patient Dosed in Phase I Clinical Trial for RAG-17 in SOD1-ALS

Ractigen Therapeutics Announces First Patient Dosed in Phase I Clinical Trial for RAG-17 in SOD1-ALS

NANTONG and SUZHOU, China, Dec. 24, 2024 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated to developing RNA-based innovative therapies, today announced the successful dosing of the first patient in the Phase I...

menu
menu